Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
NCT02423954 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33
Last updated 2018-07-02
Summary
Determine Phase 2 dose of study drug
Conditions
- Advanced Cancer
- Pancreatic Cancer
- Renal Cell Cancer
- Non Small Cell Lung Cancer
- Colorectal Carcinoma
- Endometrial
- Uterine
Interventions
- DRUG
-
Temsirolimus
- DRUG
- DRUG
-
Irinotecan + capecitabine
- DRUG
Sponsors & Collaborators
-
Western Regional Medical Center
lead OTHER
Principal Investigators
-
Jordan Waypa, MSN, FNP · Western Regional Medical Center
-
Cynthia Lynch, MD · Western Regional Medical Center
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-04-30
- Primary Completion
- 2017-11-01
- Completion
- 2017-11-01
Countries
- United States
Study Locations
More Related Trials
-
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
NCT02750514 ·Status: TERMINATED ·Phase: PHASE2
-
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
NCT03342417 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
NCT03048136 ·Status: WITHDRAWN ·Phase: PHASE3
-
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
NCT03121417 ·Status: WITHDRAWN ·Phase: PHASE2
-
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
NCT03366766 ·Status: TERMINATED ·Phase: PHASE2
-
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT04514484 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
NCT03770299 ·Status: WITHDRAWN ·Phase: PHASE2
-
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
NCT00226590 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
NCT02864251 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04623775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
NCT03149120 ·Status: WITHDRAWN ·Phase: PHASE2
-
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
NCT03158129 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
NCT05543629 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
NCT03256136 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT02954991 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
NCT02259621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
NCT03574649 ·Status: WITHDRAWN ·Phase: PHASE2
-
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT03041181 ·Status: TERMINATED ·Phase: PHASE2
-
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
NCT03829436 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
NCT03023904 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT02477826 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
NCT04151563 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
NCT05500092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2